Can targeting Polθ inhibitors selectively kill ecDNA-driven tumors in patients?

Lens adapted to this topic: ecDNA-specific vulnerability hypothesis

A more exploratory interpretation is that ecDNA-driven tumors may be unusually dependent on DNA-repair processes because circular, highly transcribed DNA creates replication stress and structural instability. This could make Polθ inhibition useful, potentially alongside PARP inhibition or other treatments. Yet the supplied evidence supports this as a testable hypothesis, not as demonstrated ecDNA selectivity or a proven patient treatment effect.

• Because ecDNA can generate replication-transcription conflicts and requires mechanisms that preserve its structure, repair-pathway dependence could be therapeutically exploitable.
• Polθ inhibitors create DNA-repair stress and selectively kill HR-deficient models, providing a mechanistic basis for investigating whether some ecDNA tumors are especially dependent on Polθ.
• ecDNA status might complement, rather than replace, HR-deficiency biomarkers when selecting patients for Polθ-inhibitor trials.
• The available sources do not demonstrate that ecDNA itself causes Polθ dependence or that patients with ecDNA-driven tumors respond selectively.

Featured sourceDiscovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors | Nature Communicationsnature.com6 sourcesView sources